EASSI - Evaluation of the Safety of Self-Administration With Icatibant

Hereditary Angioedema Clinical Trial

— EASSI  

Official title:

Open Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00997204
• Other study ID #: JE049-3101
• Secondary ID: 2008-000071-25
• Status: Completed
• Phase: Phase 3
• Start date: September 25, 2009
• Est. completion date: June 22, 2011

Study information

• Verified date: May 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.

Description:

This Phase IIIb study was multi-center and open-label with a single dose level. Subjects with a documented diagnosis of HAE Type I or II were eligible to participate in this trial. Eligible subjects included those who had received treatment for HAE with icatibant in previous clinical trials, or subjects who had been previously treated with the marketed product Firazyr® and subjects who were naïve to icatibant treatment.

All subjects were trained on the method of self-administration at their enrollment visit (Visit 1).For the training sessions, a syringe pre-filled with 3 mL placebo solution was used in place of icatibant. Comprehensive educational material and instructions including pictograms were developed for the subjects to illustrate the method of self-administration and use of the Patient Diary. The training material provided additional information on how to self-diagnose an HAE attack and how to decide on the necessity to treat.In addition, instructions were provided on what to do in case of a laryngeal attack.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 151
• Est. completion date: June 22, 2011
• Est. primary completion date: June 22, 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Each patient must meet the following criteria to be enrolled in this study.

1. Males and females 18 years of age at the time of informed consent

2. Documented diagnosis of HAE Type I or II based on ALL of the following criteria:

• Family and/or medical history

• Characteristic attack manifestations, recurrent attacks

• Historical functional C1-INH <50% normal values

3. Women of childbearing potential must use consistently and correctly a highly effective, adequate method of birth control (failure rate less than 1% per year) - sexual abstinence or have a vasectomised partner during the duration of the study. Hormonal contraception can be continued if verified by a physician that it doesn't affect the course of HAE attacks.

4. Mental and physical condition allowing patients to complete baseline assessment, to self-administer icatibant and to follow other study procedures.

5. Ability to provide signed written informed consent after all aspects of the study have been explained and discussed with the patient.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study.

1. Participation in a clinical trial of another investigational medicinal product within the past month (except a previous icatibant study).

2. Diagnosis of angioedema other than Type I or Type II HAE.

3. Evidence of symptomatic coronary artery disease based on medical history, in particular, unstable angina pectoris or severe coronary heart disease.

4. Congestive heart failure (NYHA Class 3 and 4).

5. Stroke within the past 6 months.

6. Treatment with angiotensin converting enzyme (ACE) inhibitor.

7. Pregnancy and/or breast-feeding.

8. In the opinion of the investigator: mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study.

9. In the opinion of the investigator: unlikely to comply with the protocol, for example, uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study for any reason.

10. In the opinion of the investigator: inability to manage study medication or self-administration of an injection.

Related Conditions & MeSH terms

• Angioedema
• Hereditary Angioedema

Intervention

Drug:
• Icatibant
Single subcutaneous injection of icatibant, 30 mg

Locations

Country	Name	City	State
Argentina	Hospital Britanico Unidad de Alergia	Buenos Aires
Austria	Universitätsklinik für Dermatologie und Venerologie	Graz
Denmark	Odense Universitetshospital-OUH	Odense	I Og Alergicentret
France	Centre Hospitalier Universitaire/ Service de Dermatologie	Angers	Angers Cedex 09
France	Clinique Universitaire de Medicine/ Centre National de reference	Grenoble	Grenoble Cedex 09
France	Hopital Claude Huriex/ Service de medicine interne	Lille	Lille Cedex
France	Hospital Edouaed Herriot	Lyon	Cedex 03
France	Hopital Europeen Georges Pompidou Immunologie Clinique	Paris	Paris Cedex 15
Germany	Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie, Charité	Berlin
Germany	Universitäts-Hals-Nasen-Ohren-Klinik Essen, Universität Duisburg-Essen	Essen
Germany	Klinkum der Johann Wolfgang Goethe-Universitat	Frankfurt am Main
Germany	Hautklinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg-Universität	Mainz
Israel	Bnai-Zion M.C. Clinical Immunology and Allergy Division	Haifa
Israel	Tel Aviv Sourasky Medical Center - Allergy Unit	Tel Aviv
Israel	The Chaim Sheba Medical Center, The Allergy and Clinical Immunology Unit	Tel Hashomer
Italy	Ospedale Luigi Sacco	Milano
Italy	Universita degli Studi di Napoli 'Federico II'	Napoli,
Spain	Hospital Universitario Vall de Hebrón / Sección de Alergia, Escola Infermeria	Barcelona
Spain	Hospital General Universitario Gregorio Maranon	Madrid
Spain	Hospital Universitario La Paz, Servicio de Alergia	Madrid
Spain	Hospital Universitario La Fe, Servicio de Alergia	Valencia
Switzerland	Luzerner Kantonsspital	Luzern
Switzerland	Universitätsspital Zürich / Dermatologische Klinik	Zurich
United Kingdom	Southmead Hospital, Department of Immunology	Bristol
United Kingdom	Barts & The London NHS Trust, Pathology and Pharmacy Building	London
United Kingdom	Derriford Combined Laboratory, Department of Clinical Immunology & Allergy	Plymouth

Sponsors (2)

Lead Sponsor	Collaborator
Shire	Jerini AG

Countries where clinical trial is conducted

Argentina,  Austria,  Denmark,  France,  Germany,  Israel,  Italy,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Events in Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant	Clinical safety of self-treatment of acute HAE attacks with s.c. injections of icatibant was assessed by calculating the number of AEs occurred during the study. Only those adverse events occurring up to the earlier of 7 days from the start of the naive phase, study discontinuation and start of the self-administration phase are assessed. The Local Tolerability Assessment tool was used. Subjects and Investigators graded erythema/reddening, swelling, burning, pruritus/itching, warm sensation, and skin pain on a 0 to 3 severity scale.	7 days from the beginning of each phase
Secondary	Clinical Efficacy of Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant, Time to Symptom Relief Using VAS Score for a Single Primary Symptom by Patient Cohort	Subjects assessed angioedema attack symptoms using the visual analogue scale (VAS) for skin pain, skin swelling and abdominal pain. The VAS is a continuous scale comprised of a 100 mm in length line, anchored by 2 verbal descriptors, one for each symptom extreme 0 (no pain) and 100 (worst pain). The respondent is asked to place a mark on the VAS line (any where between 0 and 100 mm) at the point that represents their pain intensity. The score is determined by measuring the distance (mm) on the line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity. Score interpretation is: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm). Symptom relief is defined as at least a 50% reduction in a pre-dose VAS score of 30 mm or greater. The time to onset of symptom relief is defined as the first of 3 consecutive assessments at which symptom relief was observed.	48 hours post-dose